DISCOVER is a Marie Sklodowska-Curie and Horizon 2020 project bringing together researchers in the fields of cell death signalling, immunology, protein structural chemistry, drug design, bioinformatics and computational biology in a network that will exchange reagents, technologies and knowledge. This cross-sectoral network will form a synergistic environment that aims to aid in understanding how the…
The INSPIRED or Interfere to Suppress or Promote IRE1 programme is a Marie Sklodowska-Curie and Horizon 2020 project that aims to establish an inter-sectoral, interdisciplinary network of experts in IRE1 biology and drug development, who share their knowledge and expertise to develop new treatments for cancer and neurodegenerative diseases.
Precision Oncology Ireland
Precision Oncology Ireland (POI) is a consortium of five Irish Universities, six Irish Charities, and seven industry partners aiming to develop new diagnostics and therapeutics for personalised cancer treatment. The consortium is part-funded by Science Foundation Ireland under their Strategic Partnership Programme, and is co-ordinated by Systems Biology Ireland, at University College Dublin. Website: https://www.precisiononcology.ie/
SAND is a Marie Sklodowska Curie Innovative Training Network proposal directly addressing the need for high-level training and career paths to address the challenges of elucidating the crosstalk of autophagy and secretion and their role in neurodegeneration. Cell Stress Discoveries is part of SAND with a project “Modulation of Endoplasmic Reticulum (ER) proteostasis in neurodegenerative…
TREATMENT is a Marie Sklodowska Curie Innovative Training Network proposal directly addressing the need for high-level training and career paths in risk evaluation of drug induced metabolic dysfunctions, a relevant aspect, so far unexplored by traditional toxicology studies, but urgently needed to challenge current severe limitations of health care interventions. https://itn-treatment.eu
BRAF mutant (MT) colorectal cancer (CRC) accounts for 10-15% of CRC and represents the subgroup with the worst overall survival. There is an urgent need to identify strategies that hit the ‘Achilles Heel’ in poor prognostic BRAFMT CRC. Preliminary data from the host lab have shown that BRAFMT CRC cells are vulnerable to disturbances in…